Abstract
Targeted lung denervation (TLD) is a novel bronchoscopic treatment for COPD GOLD-D patients. The TLD treatment disrupts the peribronchial vagal innervation of the airways by radiofrequency energy, and consequently decreases the release of acetylcholine [1]. TLD has shown to have a positive effect on the occurrence of COPD exacerbations after treatment [1]. Recently, it was shown that 3 years after TLD treatment the lung function was stable compared to before treatment [2]. However, it is not known how this relates to the lung function decline before treatment.
Highlights
DJS reports grants, non-financial support and other from Nuvaira, USA, during the conduct of the study.
BD reports personal fees from Nuvaira, during the conduct of the study.
FH received personal money for adboard activities and lecture fees from Pulmonx, BTG, Olympus and Uptake.
Summary
DJS reports grants, non-financial support and other from Nuvaira, USA, during the conduct of the study.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
